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Imatinib induces a complete cytogenetic regression in a large percentage of patients affected by chronic myeloid leu-
kemia (CML) until mutations in the kinase domain of BCr-aBL appear. alternative strategies for CML patients include the 
inhibition of phosphatidylinositol 3-kinase (PI3K)-akt-mammalian target of rapamycin (mtor) pathway, which is consti-
tutively activated in leukemia cells and seems important for the regulation of cell proliferation, viability, and autophagy. 
In this study, we verified the effect of imatinib mesylate (IM), alone or in association with Ly294002 (Ly) (a specific PI3K 
protein tyrosine kinase inhibitor) or 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]-pyrimidine (PP1) (a Src tyro-
sine kinase inhibitor), on viability, intracellular calcium mobilization, apoptosis, and autophagy, in order to verify possible 
mechanisms of interaction. our data demonstrated that PP1 and Ly interact synergistically with IM by inducing apoptosis 
and autophagy in Bcr/abl+ leukemia cells and this mechanism is related to the stress of the endoplasmic reticulum (er). 
our findings suggest a reasonable relationship between apoptotic and autophagic activity of tyrosine kinase inhibitors 
(tKIs) and the functionality of smooth er Ca2+-atPase and inositol triphosphate receptors, independently of intracellular 
calcium levels. therapeutic strategies combining imatinib with PI3K and/or Src kinase inhibitors warrant further investi-
gations in Bcr/abl+ malignancies, particularly in the cases of imatinib mesylate-resistant disease.
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Introduction
Therapeutic treatment with imatinib, a small-molecule drug 
that competitively inhibits the binding of ATP to the BCR-ABL 
tyrosine kinase, involves a complete cytogenetic regression of a 
large percentage of CML-treated patients1-3 but is ineffective in 
treating cases of patients with mutations in the kinase domains 
(Y253F/H; E255K/V; T315I; H396P/R43,44; M244V; M351T 
o F359V), for which the daily dose needs to be increased.4-9 In 
addition to increasing dosage, the search for and selection of new 
tyrosine kinase inhibitors is of great interest.10-13
Approaches to overcome drug resistance combine imatinib 
mesylate with other signaling inhibitors, such as flavopiridol,14 
farnesyltransferase inhibitors,15 histone deacetylase inhibitors,16 
and Akt inhibitors.17 It is commonly believed that the RAS/
RAF-1/MEK1/2/ERK1/2 signaling pathway mediates survival 
signaling in several transformed cell types, including Bcr/Abl+ 
leukemia cells.18,19 Such findings have prompted the clinical 
development of several pharmacological MEK1/2 inhibitors, 
including PD184352 (or CI-1040), PD032591, and AZD6244 
(ARRY142886).20-23 Results obtained from early clinical tri-
als indicate that it is feasible to achieve the interruption of 
MEK1/2/ERK1/2 pathway with desired pharmacodynamics 
effect (e.g., ERK1/2 inactivation), giving benefits to Bcr/Abl+ 
leukemia cells, including those resistant to imatinib mesyl-
ate.20,24 New therapeutic approaches are thus warranted,25 and 
inhibition of the phosphatidylinositol 3-kinase (PI3K)-Akt-
mammalian target of rapamycin (mTOR) pathway may become 
a future strategy, since this pathway is constitutively activated in 
the leukemia cells of most patients and seems important for the 
regulation of cell proliferation, viability, and autophagy.26-28 The 
PI3K/AKT/mTOR pathway is important for intracellular 
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signaling of apoptosis in cancers29-32 such as breast,33 and non-
small cell lung cancers.34
It has been widely demonstrated that Ca2+ signaling plays a 
pivotal role in proliferation of cancer cells. Several studies have 
demonstrated that even minor disruptions in either total Ca2+ 
levels or subcellular distribution can modulate the apoptotic 
response to a large number of stimuli. In most cell types, the 
endoplasmatic reticulum is the primary intracellular store of 
Ca2+, where it participates in the folding, modification, and sort-
ing of newly synthesized proteins. Homeostasis between Ca2+ 
stores and cytosolic Ca2+ is maintained by ER-resident channels 
and transporters. The primary mechanism for ER Ca2+ influx 
is the smooth ER Ca2+-ATPase (SERCA), which mediates store 
filling. The release of Ca2+ from the ER is mediated by the inositol 
triphosphate receptor (IP3R). Recent studies suggest that IP3R-
activated depletion of ER stores is also involved in the regulation 
of Ca2+ influx from the extracellular environment, a phenomenon 
known as capacitative Ca2+ influx.35
We have previously demonstrated that peripheral blood mono-
nuclear cells derived from patients affected by chronic myeloid 
leukemia (CML) showed a deregulated calcium homeostasis and 
oxidative stress36 and that IM treatment, in vivo and in vitro, 
was able to modulate the intracellular calcium concentration of 
peripheral blood mononuclear cells of CML patients by acting at 
the level of InsP3 receptor in the endoplasmic reticulum as well as 
at level of the purinergic receptors on plasma membrane.
The role of Ca2+ in the regulation of autophagy has been 
investigated since 1993.37 This study indicated that both an 
increase and a decrease in the cytosolic [Ca2+]
i
 was able to sup-
press autophagy. Further reports did not clarify the complex 
role of Ca2+ in autophagy, and apparently contrasting results 
have been published.38 In fact, Gordon et al. demonstrated 
that in hepatocytes of rats, agents such as thapsigargin (TG), 
2,6-di-(tert-butyl)-1,4-benzohydroquinone (tBuBHQ), and 
ionomycin, that increase cytosolic Ca2+ levels by releasing 
Ca2+ from intracellular stores, strongly inhibit autophagy. 
These results suggest that depletion of sequestered Ca2+ 
from intracellular stores rather than cytosolic Ca2+ is a 
common mechanism of inhibition. Recently, Decuypere 
et al. demonstrated that in Hela cells a tight interrelation 
between intracellular Ca2+ signaling and autophagy stimula-
tion. Ins(1,4,5)P3R-mediated Ca2+ signaling was critical for 
autophagy stimulation, since the Ca2+ chelator BAPTA-AM 
as well as the xestospongin B (Ins[1,4,5]P3R inhibitor) abol-
ished the increase of LC3-mediated lipidation.39
Previous findings reported that cytosolic Ca2+ may stim-
ulate autophagy, but these studies predominantly involved 
Ca2+-mobilizing triggers such as ionomycin (IONO), TG 
or Cd2+.40-42 These treatments led to disruption of intra-
cellular Ca2+ homeostasis and subsequent stimulation of 
autophagy through a Ca2+-dependent pathway.
The purpose of this work was to study, in K562 cells and 
peripheral blood mononuclear cells from newly diagnosed 
CML patients (CML-PBM), the effect of imatinib mesylate 
(IM), a specific and potent BCR/ABL protein tyrosine kinase 
inhibitor, alone or in association with LY294002 (LY) (a 
specific PI3K protein tyrosine kinase inhibitor) or 4-Amino-
5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]-pyrimidine 
(PP1) (a Src tyrosine kinase inhibitor), on viability, mobili-
zation of intracellular calcium, apoptosis, and autophagy in 
order to verify possible mechanism of interaction.
Results
Cytotoxicity of TKIs in K562 and CML-PBL cells
In a first series of experiments we examined the cyto-
toxic effects of IM, PP1, and LY. K562 or CML-PBL cells 
were incubated with drugs for 24 h, and the cytotoxicity 
was determined by MTT assay (Fig. 1).
Figure 1. Cytotoxic effect of IM, PP1 and Ly in K562 or CML-PBM cells. Increasing 
concentrations (range 0.2–10 μM) of IM, PP1, or Ly were incubated with 106 of 
K562 or CML-PBM cells for 24 h at 37 °C in humidified atmosphere of 5% carbon 
dioxide in air. Data represent the mean of 4 independent experiments each in 
duplicate; bar represent S.D. (*P < 0.05 vs. control cells). (A and B) 106 of K562 or 
CML-PBM were incubated with 1 μM of IM alone or in association with equimo-
lecular concentrations of PP1 or Ly. Data represent the % variation respect IM 
alone. (**P < 0.05 vs. IM alone).
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The IC
50
 of IM, PP1, and LY were, respectively, 2.4 ± 0.31, 2.7 
± 0.33, and 1.9 ± 0.24 μM in K562 and 1.9 ± 0.25, 2.4 ± 0.27, and 
2.0 ± 0.16 μM, respectively, in CML-PBM cells. Panels A and B 
show the cytotoxicity data obtained using PP1 or LY (1 μM) at 
equimolecular doses with IM. As shown, PP1 and LY increased 
IM-induced cytotoxicity of 36% and 34%, respectively, in K562 
cells and of 41% and 48%, respectively, in CML-PBM cells.
IM, PP1, and LY inhibit calcium mobilization induced 
by TG or InsP3
It has been established that low and high Bcr/Abl-
expressing cells show impaired ER homeostasis and are unable 
to activate ER calcium-mediated apoptotic pathways.43,44 
Our studies have shown that in vivo IM treatment is able to 
modulate the intracellular calcium concentration of periph-
eral blood mononuclear cells from CML patients.45 Figure 2 
shows the results obtained by using increasing concentrations 
(range 0–50 μM) of IM, PP1, or LY on the mobilization of 
intracellular calcium induced by 2 μM TG. K562 and CML-
PBM cells were loaded with FURA-2/AM and balanced for 
10 min in a calcium-free medium for determination of TG 
activity. In K562 cells, IM, PP1, and LY reduced the mobili-
zation of [Ca2+]
i
 induced by TG in a dose-dependent manner 
with an IC
50
 of 7.7 ± 0.71, 10.4 ± 0.98, and 8.6 ± 0.87 μM, 
respectively, while in CML-PBM cells, the IC
50
 was of 7.1 ± 
0.82, 9.4 ± 0.88 and of 8.8 ± 0.90 μM, respectively. Panel A 
shows the results obtained using IM (7.7 μM) with equimo-
lecular doses of PP1 or LY in K562 cells, while panel B shows 
the results obtained using IM (7.1 μM) with equimolecular 
doses of PP1 or LY in CML-PBM cells. PP1 and LY showed a 
synergistic effect with IM by decreasing the calcium levels of 
36% and 38%, respectively, in K562 and of 43% and 49%, 
respectively, in CML-PBM cells.
Figure 3 shows the results obtained using increasing con-
centrations (range 0–50 μM) of IM, PP1 and LY on the 
intracellular calcium mobilization induced by 5 μM InsP3 in 
K562 and CML-PBM cells. In K562 cells, IM, PP1, and LY 
reduced InsP3-induced intracellular calcium mobilization in 
a dose-dependent manner with an IC
50
 of 7.5 ± 1.1, 10.6 ± 1.7, 
and 8.8 ± 0.95 μM, respectively, while in CML-PBM cells, 
the IC
50
 was of 6.9 ± 0.63, 10.4 ± 0.89, and of 8.5 ± 0.84 μM, 
respectively. Panel A shows the results obtained using IM (7.5 
μM) with equimolecular doses of PP1 or LY in K562 cells, 
and panel B shows the results obtained using IM (6.9 μM) 
with equimolecular doses of PP1 or LY in CML-PBM cells. 
PP1 and LY showed a synergistic effect, with IM decreasing 
calcium levels of 36% and 34%, respectively, in K562 and of 
36% and 44%, respectively, in CML-PBM cells.
It is important to note that IM, PP1 and LY utilized alone, 
did not produce significant effects on the intracellular cal-
cium mobilization induced by 10 μM of IONO (an aspecific 
ionophore) (data not shown).
Synergistic effect of PP1 and LY on IM-induced apopto-
sis and autophagy
The apoptotic activity of IM, PP1, and LY used alone 
or in association was evaluated by assaying the levels of oli-
gonucleosomes in K562 and CML-PBM cells. Cells were 
incubated for 24 h with IM, PP1 and LY (1 μM) alone or in 
association at equimolecular doses. As showed in Figure 4, IM, 
PP1, and LY induced apoptosis in K562 and CML-PBM cells 
with O.D. values of 0.183 ± 0.025, 0.097 ± 0.012, 0.083 ± 0.0092 
and of 0.206 ± 0.029, 0.099 ± 0.014, 0.101 ± 0.0098, respectively.
PP1 and LY showed a synergistic effect with IM when used in 
association at equimolecular doses in CML-PBM cells, increasing 
Figure  2. In vitro activity of increasing concentration of various tyrosine 
kinase inhibitors on calcium levels induced by tG in K562 or CML-PBM cells. 
106 cells were incubated with 2 μM of tG alone or with increasing concentra-
tions (0–50 μM) of IM, Ly, or PP1 (KrH medium calcium free). (A) represents 
the effect of 7.7 μM IM alone or in association with equimolecular doses 
of PP1 or Ly in K562 cells. (B) represents the effect of 7.1 μM IM alone or in 
association with equimolecular doses of PP1 or Ly in CML-PBM cells. Data 
represent the [Ca2+]i values (mean ± S.D.) obtained in 4 distinct experiments 
performed in duplicate. (*P < 0.05 vs. tG alone; ** P < 0.05 vs. IM alone).
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O.D. values from 0.206 ± 0.029 to 0.274 ± 0.024 (33.0%) and 
0.334 ± 0.039 (62.1%), respectively. The same scenario was 
observed in K562 cells, in which PP1 and LY shifted the O.D. 
values from 0.183 ± 0.025 to 0.234 ± 0.026 (27.8%) and 0.261 ± 
0.022 (42.6%), respectively.
The autophagic activity of IM, PP1, and LY used alone or in 
association was evaluated by western blot analysis of LC3II protein 
levels in K562 and CML-PBM cells. Cells were incubated for 6 h 
with IM, PP1, and LY (1 μM) alone or in association at equimo-
lecular doses. Figure 5 shows IM, PP1, and LY induced autophagy 
in K562 and CML-PBM cells with A.U. values of 42.8 ± 4.5, 28.9 
± 3.1, 25.3 ± 2.1 and 53.3 ± 6.2, 24.7 ± 2.1, 22.9 ± 1.9, respectively.
PP1 and LY showed a synergic effect with IM when used in 
association at equimolecular doses in CML-PBM cells increasing 
A.U. values from 53.3 ± 6.2 to 77.8 ± 8.9 (45.9%) and 96.5 ± 10.3 
(80.3%), respectively. The same scenario was observed in K562 
cells in which PP1 and LY shifted A.U. values from 42.8 ± 4.5 to 
60.8 ± 6.9 (42.0%) and 71.3 ± 8.1 (66.5%), respectively.
Intracellular calcium modulation mediates IM, PP1 and LY 
synergistic effect
In order to verify the correlation between induction of apop-
tosis and/or autophagy, IP3/IP3R, or SERCA signaling cascades, 
we used the thapsigargin (TG) (specific inhibitor of the SERCA 
channels and inducer of mTOR-independent autophagy), lith-
ium chloride (Li) (a regulator of the levels of inositol-1, 
4,5-trisphosphate and inhibitor of InsP3 receptors and 
autophagy inducer),46,47 IONO (an aspecific ionophore), 
and the BAPTA-AM (a chelator of intracellular calcium) in 
association with IM, PP1, and LY.
Figure 6 shows the results obtained using TG (2 μM), 
Li (10 mM), IONO (10 μM), and BAPTA-AM (10 μM) 
alone and in association with IM, PPI, and LY on apopto-
sis. The TG treatment increased O.D. values in K562 and 
CML-PBM cells from 0.027 ± 0.004 to 0.158 ± 0.021 and 
from 0.039 ± 0.0035 to 0.205 ± 0.022, respectively. Lithium 
treatment increased O.D. values in K562 and CML-PBM 
cells from 0.027 ± 0.004 to 0.112 ± 0.012 and from 0.039 
± 0.0035 to 0.154 ± 0.012, respectively. BAPTA-AM and 
IONO produced no effect on apoptosis.
In K562 cells treated with IM, IM with PP1, and IM 
with LY, TG (2 μM) led to a further increase in apoptosis 
of 34.7%, 34.8%, and 38.6%, respectively. Even in CML-
PBM cells treated with IM, IM with PP1, and IM with LY, 
TG led to an increase in apoptosis of 27.3%, 47.8%, and 
38.5%, respectively.
The same scenario was observed using Li (10 mM) in 
association with IM, PPI, and LY. In fact, in K562 cells 
treated with IM, IM with PP1, and IM with LY, Li led to a 
further increase in apoptosis of 33.0%, 72.3%, and 86.6%, 
respectively. In CML-PBM cells, Li (10 mM) led to a fur-
ther increase in apoptosis of 58.4%, 90.2%, and 85.0%, 
respectively.
On the contrary, BAPTA-AM (10 μM) used in associa-
tion with IM, IM with PP1, and IM, significantly reduced 
drug-induced apoptosis. In fact, in K562 cells treated with 
IM, IM with PP1, and IM with LY, BAPTA-AM reduced 
apoptosis by 36.4%, 40.8%, and 46.3%. Likewise, in 
CML-PBM cells, BAPTA-AM reduced apoptosis by 48.1% 
in IM-treated cells, 77.2% in IM + PP1 treated cells, and 
56.0% in IM + LY-treated cells. In K562 and CML-PBM 
cells, IONO used in association with IM, IM with PP1, 
and IM with LY produced no effect on apoptosis (data not 
shown).
Figure 7 shows the results obtained on autophagy using 
TG (2 μM), Li (10 mM), and BAPTA-AM (10 μM) alone 
and in association with IM, PPI, and LY.
The TG treatment increased autophagy in K562 and 
CML-PBM cells from 12.7 ± 2.1 to 67.5 ± 7.9 and from 
Figure  3. In vitro activity of increasing concentrations of various tyrosine 
kinase inhibitors on calcium levels induced by InsP3 in K562 or CML-PBM cells. 
106 cells were incubated with 5 μM InsP3 alone or with increasing concentra-
tions (0–50 μM) of IM, PP1, or Ly (KrH medium, calcium-free). (A) represents the 
effect of 7.5 μM IM alone or in association with equimolecular doses of PP1 or Ly 
in K562 cells. (B) represents the effect of 6.9 μM IM alone or in association with 
equimolecular doses of PP1 or Ly in CML-PBM cells. Data represent the [Ca2+]i 
values (mean ± SD) obtained in 4 distinct experiments performed in duplicate. 
(*P < 0.05 vs. InsP3 alone; ** P < 0.05 vs. IM alone).
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13.2 ± 1.8 to 69.4 ± 8.8 (A.U. values), respectively. Lithium treat-
ment increased autophagy in K562 and CML-PBM cells from 
12.7 ± 2.1 to 51.4 ± 7.3 and from 13.2 ± 1.8 to 53.9 ± 6.5, respec-
tively. BAPTA-AM and IONO produced no effect on apoptosis.
Cellular Ca2+ homeostasis has been reported to be per-
turbed by ER stress and to be causally linked to the induction 
of autophagy.48 Consistent with this, we observed, in K562 cells 
treated with IM, IM with PP1, and IM with LY, that TG (2 μM) 
increased autophagy from 42.9 ± 7.5 to 63.7 ± 7.5, from 60.8 ± 
7.2 to 93.7 ± 8.1, and from 71.2 ± 7.9 to 91.5 ± 7.6, respectively. 
Also, in CML-PBM cells treated with IM and IM with PP1, TG 
led to an increase in autophagy from 52.7 ± 6.4 to 82.8 ± 9.2, 
from 78.3 ± 6.7 to 94.8 ± 8.7, and from 87.0 ± 7.4 to 98.1 ± 10.2, 
respectively.
The same scenario was observed using Li (10 mM) in associa-
tion with IM, PPI, and LY. In fact, in K562 cells treated with 
IM, IM with PP1, and IM with LY, Li led to a further increase in 
autophagy from 42.9 ± 7.5 to 56.6 ± 6.1, from 60.8 ± 7.2 to 88.7 ± 
7.7, and from 71.9 ± 7.9 to 86.9 ± 7.7, respectively. In CML-PBM 
cells treated with IM and IM with PP1, Li led to an increase in 
apoptosis from 52.7 ± 6.4 to 81.4 ± 9.0, from 78.3 ± 6.7 to 94.8 ± 
8.7, and from 87.0 ± 7.4 to 98.1 ± 10.2, respectively.
On the contrary, BAPTA-AM (10 μM) used in association 
with IM, IM with PP1 and IM, significantly reduced drug-
induced autophagy. In fact, in K562 cells treated with 
IM, IM with PP1, and IM with LY, BAPTA-AM reduced 
LC3-II levels by 68.2%, 74.6%, and 79.5%, respec-
tively. Likewise in CML-PBM cells, BAPTA-AM reduced 
autophagy by 66.9% in IM-treated cells,  81.1% in IM + 
PP1 treated cells, and 83.6% in IM + LY-treated cells. In 
K562 and CML-PBM cells, IONO used in association with 
IM, IM with PP1, and IM with LY produced no effect on 
autophagy (data not shown).
Discussion
Several studies demonstrated that the alteration of ion-
ized calcium concentration in the cytosol has been impli-
cated in the initiation of secretion, contraction, and cell 
proliferation. It has been established that the endoplasmic 
reticulum can play a critical role in the regulation of pro-
liferation and apoptosis independently, or upstream, of the 
mitochondria.49 Low and high Bcr-Abl-expressing cells 
show impaired ER homeostasis and are unable to activate 
ER calcium-mediated apoptotic pathways.43 Our recent 
studies demonstrated a lower activity of InsP3-dependent 
release of calcium from stores as well as a decreased function 
of purinergic-dependent calcium channels in CML cells.36 
Moreover, Bellodi C, et al. showed, in primary CML cells 
and K562 cells, that in vitro treatment with 2 μM of IM 
induces apoptosis through inhibition of BCR/ABL protein 
and also through inhibition of the calcium release from 
the intracellular stores induced by thapsigargin.50 The data 
presented herein have shown that IM treatment, in K562 
and CML-PBM cells, is able to modulate the intracellu-
lar calcium concentration by acting on SERCA and InsP3 
receptors in the endoplasmic reticulum, and that the addition of 
equimolecular doses of PP1 or LY synergizes such activity.
Elevated cytosolic [Ca2+]
i
 concentrations were also shown to 
promote the autophagic process. Decuypere et al.38 demonstrated 
in HeLa cells that autophagy induction is also a Ca2+-dependent 
process in response to a non-Ca2+-mobilizing trigger, starvation, 
since chelating the cytosolic Ca2+ with BAPTA-AM during star-
vation blunted autophagy stimulation. In addition, he demon-
strated the important role for Ins (1,4,5) P3Rs in this process, 
since blocking Ins (1,4,5) P3Rs with Xestospongin B (a specific 
Ins [1,4,5] P3R inhibitor) also abolished LC3 lipidation, sug-
gesting that autophagy stimulation depends on proper Ins(1,4,5)
P3-mediated Ca2+ signaling, and is not only provoked by aber-
rant Ca2+ homeostasis. Another study has shown that stress of the 
ER is involved in the processes of apoptosis downregulating the 
PKR-like ER-resident kinase (PERK)44 and mTOR-independent 
autophagy. Ogata M, et al.51 demonstrated in SK-N-SH neuro-
blastoma that ER stressors, namely tunicamycin, an inhibitor of 
N glycosylation, and thapsigargin, an inhibitor of smooth ER 
Ca2+-ATPase, that JNK activation in the early phase of ER stress 
is required for autophagosome formation after ER stress but is not 
sufficient for the induction of apoptosis.52 In contrast, sustained 
activation of JNK for 24 h by ER stress could cause apoptosis.
Figure 4. activity of IM, PP1, or Ly alone or in association on intracytosolic levels 
of oligo-nucleosomes in K562 or CML-PBM cells. 106 cells were incubated for 24 
h with 2 μM IM, PP1, and Ly used alone or in association at equimolecular doses 
at 37 °C in humidified atmosphere of 5% carbon dioxide in air. Data represents 
mean of absorbance (o.D.) ± SD obtained in 4 distinct experiments performed 
in duplicate. (*P < 0.05 vs. basal levels. **P < 0.05 vs. IM alone).
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In the present report, we demonstrated for the first time that 
PP1, a Src kinase inhibitor, and LY294002, a specific PI3K tyro-
sine kinase inhibitor, interact synergistically with IM in induc-
ing apoptosis and autophagy in Bcr/Abl+ leukemia cells and 
are related to the stress of the endoplasmic reticulum. In fact, 
experiments performed with BAPTA-AM, a calcium chelator, 
significantly inhibited apoptosis and autophagy induced by TG 
and Li (a regulator of the levels of inositol-1, 4,5-trisphosphate 
and inhibitor of InsP3 receptors). Our data showed a reasonable 
relationship between the apoptotic and autophagic activity of the 
TKIs utilized and the functionality of receptors SERCA and Ins 
(1,4,5) P3 independently of intracellular calcium levels. In fact 
the inhibition of SERCA and InsP3 receptors observed in our 
experiments has led to an increase of autophagy and apoptosis, 
while the ionophore used had no effect.
In conclusion, our findings suggest that therapeutic strategies 
combining Imatinib with IP3K and/or Src kinase inhibitors war-
rant further investigation in Bcr/Abl+ malignancies, particularly 
in the cases of imatinib mesylate-resistant disease.
Materials and Methods
Chemicals
Imatinib (IM) kindly provided from Novartis SpA; RPMI-
1640 from Labtek Laboratories, Eurobio; LY294002, 4-Amino-5-
(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]-pyrimidine (PP1), 
lithium chloride (Li), Thapsigargin (TG), Inositol 
1,4,5-triphosphate (InsP3), Ionomycin (IONO), 
Phytohaemagglutinin (PHA), fetal calf serum (FCS), 
hystopaque, propidium iodide (PI), were obtained from 
SIGMA.
Patients
For this study, 15 volunteer patients with CML (7 
males and 8 females; mean age 53 y; range 35–57 y) 
were processed at the time of diagnosis. Eligible patients 
have been diagnosed with Ph+ CML-CP (Cytogenetic 
analysis showed that Ph chromosome were 100% of 
positive). Chronic phase was defined by the presence 
of <15% blasts, <20% basophils, and <30% blasts plus 
promyelocytes in the peripheral blood or bone marrow.
Leukocytes preparation
Peripheral blood mononuclear cells of CML patients 
(CML-PBM) newly diagnosed were isolated using 
the modification of a method of Boyum as described 
by Florio et al.53 Briefly, human blood from patients 
and control subjects was drawn in heparin (20 U/ml), 
stratified on Ficoll-Hystopaque gradients (density 
1.077), and centrifuged for 30 min at 600 × g. The ring 
of leukocytes at the interface was collected and washed 
2 times with 5 ml of PBS. The preparation was found 
to be 89% pure by flow cytometric analysis (range 
84–91%; red blood cells 6.1%; polymorphonucleates 
2.6%; platelets 2.1%). Lymphocytes were washed by 
centrifugation for 5 min at 600 × g and re-suspended 
in RPMI 1640 supplemented with 10% fetal calf 
serum (FCS), 1% penicillin and streptomycin, 2 mM 
glutamine. Aliquots of lympho-monocytes were incu-
bated for 1 h in humidified atmosphere of 5% CO
2
 at 
37 °C in culture plastic plates. Light microscopy and 
flow cytofluorimetric analysis of stained cells demon-
strated that more than 96 ± 2% of the adherent cells 
were monocytes.
Viable lymphomonocytes (as evaluated by means of 
the trypan blue exclusion test) were seeded at 3 × 106 
cells in 6-well tissue culture plates and cultured over-
night in RPMI 1640 complete medium.
Cell line culture
The BCR-ABL-positive K562 cell lines derived 
from a patient with CML in erythroid blast phase was 
Figure 5. activity of IM, PP1, and Ly used alone or in association on autophagy in 
K562 and CLM-PBM cells. Cultures of K562 and CLM-PBM cells were incubated for 
6 h with 2 μM of IM, PP1, or Ly alone or in association at equimolecular doses at 
37 °C in humidified atmosphere of 5% Co2. Cells were scraped, harvested, lysed, 
and subjected to western blot analysis with antibodies against actin and LC3II. 
(A and B) actin protein levels were detected to ensure equal protein loading. 
Densitometric analysis of blots relative to LC3II. results are expressed as the mean 
of arbitrary units (a.U.) ± SD of 4 independent experiments. (*P < 0.05 vs. basal lev-
els. ** P < 0.05 vs. IM alone).
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provided by ATCC. K562 cells were cultured in RPMI 1640, sup-
plemented with 10% (v/v) heated-inactivated fetal bovine serum 
(FBS) 100 U ml-1 of penicillin and 100 μg of streptomycin ml 
in a humidified atmosphere with 5% CO
2
 at 37 °C. Morphology 
was determined with Wright staining of cells centrifuged onto 
slides by cytospin (100 g, 4 min; Shandon, Runcorn).54
Cytotoxicity assay
K562 or peripheral blood mononuclear cells of CML patients 
(CML-PBM) newly diagnosed (1 × 106/well) were distributed 
on a 96-well flat-bottomed plate and a final volume of 100 μL 
of RPMI medium with 10% bovine serum was obtained. After 
incubation with various drugs for 24 h, the cytotoxicity assay 
was performed with the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
dye reduction assay as previously described.55
Intracellular calcium measurement
Intracellular Ca2+ concentrations [Ca2+]
i
 were 
measured by using the radiometric fluorescent indi-
cator dye FURA-2/AM, the membrane-permeant 
form of FURA-2/AM, as previously described, 
and opportunely modified.56 Briefly, CML cells 
were washed twice in PBS in 15 ml polypropyl-
ene tubes (Falcon/Becton Dickinson Labware) 
and resuspended in Krebs Ringer (KRH) medium 
(1 × 106 cells/mL) with 3.0 mM Ca2+-sensitive 
dye FURA-2/AM for 60 min at 30 °C. We also 
added the non-ionic detergent Pluronic acid F-127 
(0.02% w/v) to each incubation batch as a dispers-
ing agent. Cells were subsequently centrifuged and 
resuspended in KRH calcium-free or containing 1 
mM CaCl2. The samples were then transferred to a 
thermostat-equipped cuvette (37 °C), maintained 
under continuous stirring and analyzed in a SPEX 
spectrophotofluorometer (2 wavelengths excita-
tions, 340 and 380 nm, and emission intensities at 
505 nm). The experiments were initiated by incuba-
tion of cell aliquots (1 × 106 cells) with several drugs 
for 5 min. After stimulation with TG or InsP3, the 
recording was continued until the end of the [Ca2+]
i
 peak. At the end of the experiment, the calibration 
was performed by determining the minimal fluo-
rescence induced by 0.1% triton X-100 in presence 
of 5 mM EGTA (Fmin) and maximal fluorescence 
induced by 3 mM CaCl
2
 (Fmax). Intracellular cal-
cium concentration was calculated according to the 
method of Grinkiewicz et al.,57 using the equation: 
[Ca2+]
i
 = 224 × [(R – Rmin)/Rmax – R)], were R 
is the experimentally determined fluorescence ratio. 
Graphs show the mean ± standard deviation values 
of 4 experiments in duplicate.
Apoptosis assay
Apoptosis was also evaluated with a cell death 
ELISA kit (Boehringer Mannheim), which utilizes 
a monoclonal antibody against histone to detect 
DNA fragments in the cytosolic fraction of lysed 
cells. Cells treated or untreated were lysed according 
to the manufacturer’s instructions. The samples were transferred 
into 96-well dishes coated with a mouse monoclonal antibody 
against histone. After incubation and washing, anti-DNA-perox-
idase was added to the wells. Cell culture supernatants removed 
from the cells after treatment (but before lysis) gave no signal, 
indicating that there were no necrotic cells during the treatment. 
The reaction was developed with the substrate supplied by the 
manufacturer, and the absorbance of the wells was read at 410 nm 
and results expressed as optical density values (O.D.).
Autophagy assay
In order to evaluate the autophagic potential of the differ-
ent therapeutic associations, the levels of microtubule-associated 
Figure 6. effect of tG (2 μM), Li (10 mM), and BaPta-aM (10 μM) used alone or in asso-
ciation with IM alone or in association with PP1 or Ly on intracytosolic levels of oligonu-
cleosomes in K562 or CML-PBM cells. Cellular suspensions were incubated for 24 h with 
2 μM tG or 10 mM Li or 10 μM BaPta alone or in association with 2 μM IM alone or in 
association with equimolecular doses of PP1 or Ly at 37 °C in humidified atmosphere of 
5% carbon dioxide in air. Data represents mean of absorbance (o.D.) ± S.D. obtained in 4 
distinct experiments performed in duplicate. (*P < 0.05 vs. control cells. ** P < 0.05 vs. IM 
alone. *** P < 0.05 vs. IM + PP1. ****P < 0.05 vs. IM + Ly).
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protein 1A/1B-light chain 3 (LC3) and its conjugated form, 
LC3-phosphatidylethanolamine conjugate (LC3-II), were 
assayed by immunoblotting. Sodium dodecyl sulfate PAGE 
and western blot analysis were performed on treated and mock-
treated K562 and CML-PBL cells, as previously described with 
some modifications.58
Cells were collected by centrifugation and resuspended in 
PBS. The pellets, obtained by centrifugation, were stored at -20 
°C. Cells were homogenized directly into lysis buffer (50 mM 
Tris pH 7.5; 150 mM NaCl; 1 mM EDTA; 0.25% deoxycho-
lic acid, 1% Triton X-100) with 20 mM sodium pyrophosphate, 
0.1 mg/mL aprotinin, 2 mM phenylmethylsulphony fluoride 
(PMSF), 10 mM sodium orthovanadate (Na
2
VO
3
), and 50 mM 
sodium fluoride (NaF). Protein concentrations were determined 
by the use of a protein assay kit (Bio-Rad Laboratories).
Equal amounts of lysate samples were boiled and loaded on 
bis/acrylamide gels, separated by electrophoresis, and proteins 
were blotted from the gel onto nitrocellulose membranes. The 
membranes were blocked with 5% bovine serum albu-
min (BSA) in Tris buffered saline (TBS: 12.5 mM 
TRIS-HCl pH 7.4; 125 mM NaCl) at room temper-
ature, washed with TBS 0.1% Tween and incubated 
with primary antibody.
The primary antibody used was rabbit anti-LC3 
(MBL International Corporation catalog no. PM036; 
1:1000 dilution). After appropriate washing steps, 
peroxidase-conjugated anti-rabbit IgG (GE Healtcare, 
catalog no. NA934) was applied for 1 h at a 1:1000 
dilution. The blots were stripped and reprobed against 
mouse anti-actin antibody (Calbiochem; cat. no. 
CP10) at 1:5000 dilution to confirm equal loading of 
proteins in each lane. Protein expression levels were 
quantitatively estimated by densitometry using a Gel 
Doc scanner (BioRad) equipped with a densitometric 
workstation. The protein concentrations were normal-
ized to the actin level and expressed as the densitomet-
ric ratio and results expressed as relative band density 
(arbitrary units-A.U.).
Total protein assay
Total proteins were determined by the method of 
Lowry et al.59
Statistical analysis
Data are expressed as mean ± standard deviation 
of 4 independent determinations. An error probabil-
ity with P < 0.05 (including P < 0.01 and P < 0.001) 
was selected as significant. All experiments were 
performed in duplicate and the mean was used for 
analysis.
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Figure  7. activity of tG (2 μM), Li (10 mM), and BaPta-aM (10 μM) used alone or 
in association with 2 μM of IM alone or in association at equimolecular doses with 
PP1 or Ly on autophagy in K562 and CLM-PBM cells. Cultures of K562 and CLM-PBM 
cells were incubated for 6 h at 37 °C in humidificated atmosphere of 5% Co2. Cells 
were scraped, harvested, lysed, and subjected to western blot analysis with antibod-
ies against actin and LC3II. (A and B). actin protein levels were detected to ensure 
equal protein loading. Densitometric analysis of blots relative to LC3II. results are 
expressed as the mean of arbitrary Units (a.U.) ± SD of 4 independent experiments. 
(*P < 0.05 vs. basal levels. ** P < 0.05 vs. IM alone).
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